natgillin/translations-raw huggingface dataset:
The composition according to claim 5, further comprising at least one compound or polypeptide selected from a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic drug, an otic drug or nasal drug, a topical drug, a nutritional drug, and a cytokine antagonist. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-23p19 antibody according to claim 1 . 
Sastav koji obuhvaća najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i najmanje jedan farmaceutski prihvatljiv nosač ili razblaživač, opcionalno dodatno obuhvaćajući najmanje jedan spoj ili polipeptid izabran od detektabilne oznake, ili reportera, TNF antagonista, anti infektivnog lijeka, lijeka kardiovaskularnog (CV) sustavaa, lijeka centralnog nervnog sustava (CNS), lijeka autonomnog nervnog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog (GI) trakta, hormonalnog lijeka, lijeka za ravnotežu tekućine ili elektrolita, hematološkog lijeka, aneoplastičnog, imunomodulacijskog lijeka, oftalmičkog, ušnog ili nazalnog lijeka, topikalnog lijeka, nutricijskog lijeka, citokina i citokin antagonista.
Hybrid yarn according to claim 7, characterised in that 5-10% fusible fibres are mixed in. 
Hibridna pređa u skladu s patentnim zahtjevom 7, naznačena time što je umiješano 5-10% topljivih vlakana.
In yet another aspect of the present invention, an effective amount of the muteins of FGF-21 herein described, or a biologically active peptide thereof, are used in the manufacture of a medicament for the treatment or prevention of one or more conditions selected from type II diabetes, obesity, or metabolic syndrome. 
Mutein ljudskog FGF-21, ili njegov biološki aktivni peptid, u skladu s patentnim zahtjevom 1, namijenjen upotrebi u liječenju pretilosti, dijabetesa tipa Il, otpornosti na inzulin, hiperinzulinemije, intolerancije glukoze, hiperglikemije, ili metaboličkog sindroma. t>&
The mouthpiece lining paper as claimed in claim 3, wherein a substance which is pasty, gel-like, sticky and/or greasy is applied to said surface areas that are located between said elevations. 
Papir za usnik kao što je navedeno u zahtjevu 4 ili zahtjevu 5, naznačeno time da je na površine (2) nanesena supstanca koja je u obliku paste, nalik gelu, ljepljiva i/ili masna.
A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10, for use as a medicament. 
Spoj s formulom (AA1) prema zahtjevu 17 naznačen time daje za uporabu kao lijek za sprječavanje ili liječenje neurodegenerativnih poremećaja, [image] pri čemu,
A method according to any of numbered embodiments 1 to 11, wherein the melt is provided on to the periphery of the first rotor at a temperature of 1450 to 1575 °C, preferably 1480 to 1550 °C. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 11, pri čemu je rastaljeni material postavljen na periferiji prvog rotora na temperaturi od 1450 do 1575"C, preporučljivo 1480 do 1550%C.
The packaged product according to any one of statements 11 to 15, wherein the MDO film has a tensile creep in the machine direction of about 0.10% to about 0.50% per um thickness of the film, as measured in accordance with ISO 899-1-2003, with following conditions: sample width of 15 mm, grip distance of 100 mm, a load of 2300 g, for 24 hours, and at 23° C. 
Pakirani proizvod u skladu s bilo kojim od patentnih zahtjeva 9, 11 ili 12, ili MDO film u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time, da MDO film ima vrijednost vlačnog puzanja u smjeru stroja od oko 0,10% do oko 0,50% po um debljine filma, izmjereno u skladu s ISO 899-1-2003 pri sljedećim uvjetima: širina uzorka od 15 mm, udaljenost prihvata od 100 mm, opterećenje od 2300 g, 24 sata 1 na 23 *C.
The composition of claims 1 or 2, wherein said KLK1 polypeptide(s) comprise an amino acid sequence having at least 95% sequence identity to amino acid residues 25-262 of SEQ ID NO:1 or SEQ ID NO:2. 
Pripravak u skladu s patentnim zahtjevima 1 ili 2, naznačen time što navedeni jedan ili više polipeptida KLK1 sadrže aminokiselinski slijed koji ima istovjetnost slijeda od najmanje 95% s aminokiselinskim ostacima 25-262 iz SEQ ID NO:1 ili SEQ ID NO:2.
The mass spectra were obtained using a Micromass Platform II (ES+ conditions) spectrometer. 
Maseni spektri su dobiveni uporabom Micromass Platform II (ES* uvjeti) spektrometra.
The compound of claim 1, selected from: 
Prsten D bira se iz grupe koja sadrži:
The filter holder according to claim 1, characterized in that material from which the closure element is made is alimentary silicone. 
Uređaj (12) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time stoje materijal od kojeg je načinjen element za zatvaranje prehrambeni silikon.
a high-pressure water gun, including a rain jet adjustment, (802), providing a jet of the above said solution on the road platform, where polluting functional liquids (lubricating oils, fuels, cooling substances, etc.) have been eventually lost by vehicles as a consequence of car accidents or breakdown; 
- - visokotlačnim vodenim topom, uključujući tuš-mlaznicu (802), koji daju mlaz gore navedene otopine na cestovnu plohu, gdje su zagađujuće funkcionalne tekućine eventualno bile prolivene iz vozila kao posljedica automobilskih nezgoda ili nesreća;
A compound of claim 3, of formula (I-K): 
Spoj sukladno patentnom zahtjevu 3, formule (I-K):
LoVo tumour cell (colorectal adenocarcinoma obtained from the ATCC) xenografts were established in the hind flank of donor mice by sub cutaneous injections of 1×107 freshly cultured cells in 100 ul of serum free media per animal. 
Ksenografti tumorskih stanica LoVo (kolorektalni adenokarcinom dobiven iz ATCC), uspostavljeni su na bočnim stražnjim stranama miševa davanjem, subkutanim injekcijama, 1x107 stanica, svježe uzgojenih u 100 ul hranjivog medija bez seruma po životinji.
the zero coefficient or coefficients located before the first non-zero coefficient such that the decoder does not affect the value of the sign hidden at this or these zero coefficients, 
navedene koeficijente koji predstavljaju blok preostalih podataka u particiji, gdje prvi nenulti koeficijent ne sadrži vrijednost predznaka; gdje je tok podataka naznačen time što:
a nucleotide sequence having at least 80% sequence identity to a nucleotide sequence of SEQ ID NO:1, 3, or 5, wherein said nucleotide sequence encodes a polypeptide having glyphosate-tolerance activity; 
nukleotidnog odsječka koji ima najmanje 80% identit odsječka nukleotidnom odsječku SEQ ID NO: 1, 3 ili 5, pri čemu rečeni nukleotidni odsječak kodira polipeptid koji ima aktivnost tolerancije na glifosat;
LDPC (Low Density Parity Check, LDPC) encoding the BCH encoded PLP data to output FECFrames (Forward Error Correction Frames), wherein the PLP data are processed by an LDPC scheme for a long LDPC FECframe or a short LDPC FECframe; 
Low Density Parity Check, LDPC), koja kodiraju vanjski kodirane PLP podatke za unaprijedno ispravljanje pogrešaka i izlaz, okvir za unaprijedno ispravljanje pogrešaka (eng. forward error correction Frame, FECFrame) za LDPC kodirane PLP podatke; sredstva (704-0) za mapiranje FEC okvira na konstelaciji kvadraturne amplitudne modulacije (eng.
The rats received food (Dietex, Vigny, France, ref. 
Å takori su imali slobodan pristup hrani (Dietex, Vigny, France, ref.
The crystalline compactin had 0.16% by weight of compactin C. 
Kristalni kompaktin je sadržavao 0.16% kompaktina C.
The tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate. 
Tablete, pilule, prašci, kapsule, dražeje i slično mogu sadržavati jedan ili više od bilo kojeg od sljedećih sastojaka, 1li spojeve slične prirode: vezivo, poput mikrokristalne celuloze, ili tragakant gume; razrjeđivač, poput škroba ili laktoze; sredstvo za raspadanje, poput škrobnih i celuloznih derivata; mazivo, poput magnezijevog stearata; a sredstvo za kliženje, poput koloidnog silicijevog dioksida; sladilo, poput saharoze ili saharina; ili aromu, poput paprene metvice ili metil-salicilata.
A method according to any one of claims 1 to 19 wherein a first quantity of 5-fluorouracil (5-FU) is administered intravenously immediately after aflibercept administration and a second quantity of 5-FU is administered intravenously after the first quantity in continuous infusion. 
Kombinacija za uporabu prema bilo kojem od zahtjeva 1 do 17 naznačena time da se prva količina 5-fluorouracil (5-FU) primjenjuje intravenozno neposredno nakon primjene aflibercepta i druga količina 5-FU se primjenjuje intravenozno nakon prve količine u kontinuiranoj infuziji.
After an additional 1 hour and 30 minutes of stirring, the mixture was brought to reflux. 
Nakon još jednog sata i 30 minuta miješanja, smjesu se zagrije do refluksa.
The method of claim 37, wherein said third polymeric material is said non-ionic polymer, the pH of the inner coating preparation being adjusted prior to coating to be at least 0.5 pH units higher than the pH threshold of the second polymeric material. 
Postupak u skladu s patentnim zahtjevom 11, naznačeno time, da je navedeni treći polimerni materijal je spomenuti neionski polimer, pH unutarnjeg pripravka za prevlačenje se namješta prije premazivanja da bude najmanje 0,5 pH jedinica veći od pH praga drugog polimernog materijala.
The use according to claim 1, characterized in that the neonatal Fc receptor and the beta-2-microglobulin are the human wild-type neonatal Fc receptor and the human wild-type beta-2-microglobulin each independently of each other with 0 to 10 amino acid residue modifications. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da su neonatalni Fc receptor i beta-2-mikroglobulin, ljudski neonatalni Fc receptor divljeg tipa te ljudski beta-2-mikroglobulin divljeg tipa, svaki nezavisan jedan od drugoga, s 0 do 10 izmjena aminokiselinskog ostatka.
In some embodiments, the antigen comprises at least a portion of myelin basic protein, acetylcholine receptor, endogenous antigen, myelin oligodendrocyte glycoprotein, pancreatic beta-cell antigen, insulin, glutamic acid decarboxylase (GAD), collagen type 11, human cartilage gp39, fp130-RAPS, proteolipid protein, fibrillarin, small nucleolar protein, thyroid stimulating factor receptor, histones, glycoprotein gp70, pyruvate dehydrogenase dehydrolipoamide acetyltransferase (PCD-E2), hair follicle antigen, A-gliaden, and human tropomyosin isoform 5, Bahia grass pollen (BaGP), peach allergen Pru p 3, alpha s 1-Caein Milk allergen, Apig1 celery allergen, Berel Brazil nut allergen, B-Lactoglobulin Milk allergen, Bovine serum albumin, Cor a 1.04 Hazelnut allergen, or Ovalbumin Egg allergen. 
Spoj sukladno zahtjevu 5, pri čemu spomenuti antigen sadrži, ili sadrži barem dio proteina odabranog iz skupine koja se sastoji od: mijelinskog bazičnog proteina, acetilkolinskog receptora, endogenog antigena, mijelinskog oligodendrocitnog glikoproteina, pankreasnog beta-staničnog antigena, inzulina, dekarboksilaze glutaminske kiseline (GAD), kolagena tipa 11, ljudskog hrskavičnog gp39, fp130-RAPS, proteolipidnog proteina, fibrilarina, malog nukleolarnog proteina, receptora za stimuliranje štitnjače, histona, glikoproteina gp70, dehidrolipoamid acetil transferaza (PCD-E2), antigen dlaka, A-gliaden, i humana tropomiozinska izoforma 5, pelud Bahia trave (BaGP), alergen breskve Pru p 3, alfa s 1-Caein mliječni alergen, Apig1l alergen celera, alergen Bere1 brazilskog oraha, B-laktoglobulin alergena mlijeka, serum alergena goveda, albumina Cor 1.04 lješnjaka, ili Ovalbumin alergena jaja.
and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5- to 10-membered chiral ring having 0-2 additional ring heteroatoms selected from N, O, or S; 
R* i R', uzeti zajedno formiraju izborno supstituirani vezujući lanac koji sadrži 2-5 atoma ugljika i 0-2 heteroatoma izabrana iz grupe koju čine O, N 1 5; pri čemu navedeni postupak sadrži:
The peptide according to any one of claims 1 to 4 for use in the treatment of cancer or for use in the manufacture of a vaccine against cancer. 
Terapijski učinkovita količina farmaceutskog sastava iz bilo kojeg od prethodnih zahtjeva za uporabu u liječenju ili sprječavanju karcinoma kod pacijenata, Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
A robotized unit for a forming machine for forming a hollow body, in particular a casing of a solid propellant engine; the unit comprising a base which can be fixed to the floor and a robotized articulated arm protruding upward from said base, and a deposit head for depositing an adhesive material coupled to a free end of said articulated arm and implemented as claimed in claim 1. 
Robotizirana jedinica za stroj za oblikovanje za oblikovanje šupljeg tijela, osobito kućišta motora na kruto gorivo, naznačena time, da jedinica ima postolje koje se može pričvrstiti na pod a robotizirana zglobna ruka pruža se prema gore od navedenog postolja i glavu za nanošenje za nanošenje adhezivnog materijala spojenu na slobodni kraj navedene zglobne ruke 1 ugrađenu u skladu s patentnim zahtjevom 1.
in a biological sample, wherein said part comprises at least 6 consecutive amino acids of the tumor-associated antigen, with said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
Observations were made prior to the first dose of the day. 
(32) Datum podnošenja prve prijave: 27.09.2007.
A compound produced by the process of any of clauses 1-50. 
PATENTNI ZAHTJEVI 1. = Postupak za dobivanje spoja koji ima formulu &
Rats were tested for their performance in the task following sub-chronic treatment with PCP (2 mg/kg i.p. 
Å takori su bili testirani na njihove sposobnosti u zadatku nakon sub-kroničnog tretiranja s PCP (2 mg/kg 1.p.
or and R2 together with the nitrogen atom to which they are attached form a 4- to 7-membered N-heterocycle, where the N-heterocycle may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, hydroxy, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, halogen and hydroxyalkyl, 
R! i R* zajedno s dušikovim atomom na koji su oni vezani tvore 4- do 7-člani N-heterocikl, gdje N-heterocikl može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, hidroksi, monofluorometil, difluorometil, trifluorometil, -hidroksikarbonil, tertbutoksikarbonil, aminokarbonil, C;-Ca-alkil, Ci-C4-alkoksi, C1-C4-alkoksi-C;-C,-alkil, halogen i hidroksialkil, ili gdje N-heterocikl može imati dva supstituenta koji, zajedno s ugljikovim atomom iz N-heterocikla na koji su oni zajednički vezani, tvore 4- do 6-člani heterociki, gdje ovaj heterocikl sa svoje strane može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, metil i etil,
separating water into the Dean-Stark trap as necessary; upon cooling to room temperature, filtering the solid precipitate through a sintered glass funnel and washing it with n-butanol-MTBE (1: 2, 600 mL) and MTBE (600 mL) respectively; and 
nakon hlađenja do sobne temperature, filtriranje istaložene čvrste supstance kroz lijevak od sinteriranog stakla i njeno ispiranje s n-butanol-MTBE (1:2,600 mL) i MTBE (600 mL), tim redom; i sušenje čvrste supstance u vakuum peći na 65°C preko noći (16 sati) da bi se dobilo 200 g žute čvrste supstance.
Y is —(C3-C8)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, or the radical of the formula III, wherein is —(CH2)r-Het in which Het is pyrrolidine or piperidine, which is unsubstituted or substituted independently of one another once, twice or three times by R1. is a)1) —C(O)—R3, 
Y je Â«(C:3-Cg)-cikloalkil, gdje cikloalkil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s RI, ili radikal formule III, gdje A3 je (CH>2),-Het, gdje je Het pirolidin ili piperidin, koji nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s R1, AS je a)1) -C(O)-R3,
The mouthpiece nozzle (5) is inserted into the cap (2) and the combined cap (2) and nozzle (5) oriented so that the lug, which attaches the cap to the strap, is aligned with the strap. 
Raspršivač kljuna (5) postavlja se u zatvarač (2) te se spojeni zatvarač (2) i raspršivač (5) orijentiraju tako da se jezičac, kojim se veže zatvarač za vrpcu, usklađuje s vrpcom.
a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having 50% or less of the protease activity of a wild-type non-mutated Tsp or is a knockout mutated Tsp gene; and a mutated DegP gene encoding a DegP protein having chaperone activity but not protease activity, wherein the cell is isogenic to an E. coli cell W3110, except for the mutated Tsp and DegP genes and optionally a polynucleotide sequence encoding a protein of interest. 
omutirani Tsp gen, pri čemu mutirani Tsp gen kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze od divljeg tipa ne-mutiranog Tsp ili je,knockout" mutirani Tsp gen; i b. - mutirani DegP gen koji kodira DegP protein koji ima aktivnost šaperona, ali ne i aktivnost proteaze, naznačena time što je stanica izogena stanici E. coli W3110, osim za mutirane Tsp i DegP gene i proizvoljno polinukleotidnu sekvencu koja kodira protein od interesa.
a gas discharge tube (GDT) captured and electrically connected between the varistor member and one of the first and second electrodes. 
gdje je metalno kućište prvog SPD-a električno povezano s PE terminalom preko metalnog kućišta drugog SPD-a.
combining the gel of step d) with the at least one further filler and/or pigment of step e). 
kombiniranja gela iz koraka d) s najmanje jednim dodatnim punilom i/ili pigmentom iz koraka e).
The composition or aerosol of claim 13, wherein the sweetener is selected from aspartame or sucrulose, a mono- or di-saccharide, lactose, sucrose, dextrose, or glucose. 
Smjesa ili aerosol iz patentnog zahtjeva 13, pri čemu se zaslađivač bira iz aspartama ili sukruloze, monosaharoze ili disaharida, laktoze, sukroze, dekstroze, ili glukoze.
More in particular the surface modifiers are selected from Pluronic™ F108, Vitamin E TGPS, Tween™ 80, and Lipoid™ EPG. One or more of these surface modifiers may be used. 
Pripravak mikro- ili nano-čestica kako je definirano u zahtjevu 6 naznačen time da je modifikator površine odabran od PluronicTM F108, Vitamin E TGPS, Tween"M 80, 1 LipoidTM EPG.
According to one embodiment the absorptive layer comprises a pigment, which, when in the form of a compacted bed, has an absorption rate from 1×10−5 ms−0.5 to 1×10−3 ms−0.5 and/or a volume uptake from 35 to 95% by volume relative to the total volume of the pigment. 
Tiskovna podloga prema bilo kojem od prethodnih zahtjeva, naznačena time da apsorpcijski sloj sadrži pigment, koji, kada je u kompaktnom obliku, ima stupanj upijanja od 1x10? ms"? do 1x10% ms"> i/ili unos volumena od 35 do 95 % volumena u odnosu na ukupni volumen pigmenta.
and R12 are the same or different and are linear alkyl, branched alkyl or cyclic alkyl having from 1 to 10 carbon atoms, or simple or substituted aryl or heterocyclic, and R12 can in addition be H, 
* Ry»'iR, suisti ili različiti i jesu nerazgranati alkil, razgranati alkil ili ciklički alkil s 1 do 10 atoma ugljika, ili nesupstituirani ili supstituirani aril ili heterocikl, a R,» dodatno može biti H;
The compound or salt according to claim 1 which is 3-[[6-[3-(hydroxymethyl)phenyl]-3-methyl-pyridine-2-carbonyl]amino]-2,4-dimethyl-benzoic acid. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-[[6-[3-(hidroksimetil)fenil]-3-metilpiridin-2karboniljamino]-2,4-dimetilbenzojeva kiselina; ili njezina farmaceutski prihvatljiva sol.
an absorptive layer being in contact with the first side of the base layer, wherein the absorptive layer has an absorption rate from 1×10-5 ms-0.5 to 1×10-3 ms-0.5 and/or a volume uptake from 30 to 95 % by volume relative to the total volume of the absorptive layer; and 
apsorpcijski (upijajući) sloj koji je u doticaju s prvom stranom osnovnog sloja, pri čemu apsorpcijski sloj ima stupanj upijanja od 1×10-5 ms-0.5 do 1×10-3 ms-0.5 i/ili unos volumena od 30 do 95 % volumena u odnosu na ukupni volumen apsorpcijskog sloja; i
or R6 and R6', together with the N-atom to which they are attached, form a (C5-C6)heterocyclyl group. 
Rs i Rs', zajedno s N-atomom na kojeg su vezani, tvore (Cs5-C,o)heterociklilnu skupinu;
The process of claim 11, wherein the solvent is an alcohol selected from the group consisting of methanol, ethanol and isopropanol. 
Postupak prema zahtjevu 10, naznačen time da je otapalo alkohol, poželjno odabrano iz skupine koja se sastoji od metanola, etanola i izopropanola.
The compound of claim 10 wherein R5 is selected from the group consisting of H, —C(═O)N(R9)2 and —CN. 
Spoj prema zahtjevu 6, naznačen time da R? je odabran iz skupine koja sadrži H, -C(=0)N(R*),, te -CN.
Apparatus according to any claim from 15 to 25, wherein said elaboration unit (50) is provided with an arithmetic module adapted to compare the value acquired by the detecting means (30) for leakage currents with pre-established or acquired in real time values. 
Uređaj u skladu s bilo kojim od zahtjeva od 15 do 25, naznačen time da spomenuta jedinica za obradu (50) ima aritmetički modul prilagođen da uspoređuje vrijednosti dobivene iz sredstva za detekciju parazitnih struja (30) s prije ustanovljenim veličinama ili veličinama dobivenim u stvarnom vremenu.
As active treatment, a 6-day course of vaginal tablets, containing 250 mg silicon-coated ascorbic acid as per the Example 2, was given once monthly for 3 months starting after menses. 
Kao aktivan lijek, 6-dnevni tijek vaginalnim tabetama, koje su sadržavale 250 mg silikonom prevučene askorbinske kiseline kao u Primjeru 2, davano je jednom mjesečno tijekom 3 mjeseca počevši nakon menstruacije.
A peptide according to claim 1, a nucleic acid or expression vector according to claim 2, a host cell according to claim 3 or 4, a CTL according to claim 6, or an antibody according to claim 7 for use as a medicament in the treatment of cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za uporabu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega.
Lipid-based microencapsulation is another technique used to taste mask the drugs. 
Mikrokapsuliranje na bazi lipida je slijedeća tehnika koja se koristi za maskiranje okusa lijekova.
Moreover, the bonding spots and/or bonding areas may be arranged side-by-side and separated from each other in the horizontal and/or vertical direction within the contact path. 
Osim toga, točke spajanja i/ili područja spajanja mogu biti raspoređeni jedni uz druge i odvojeni jedni od drugih u horizontalnom i/ili u vertikalnom smjeru unutar staze za kontakte.